# TROPiCS-04 (NCT04527991)

> Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04527991
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Gilead Sciences
- Conditions: Locally Advanced or Metastatic Unresectable Urothelial Cancer
- Interventions: Sacituzumab Govitecan-hziy; Paclitaxel; Docetaxel; Vinflunine
- Enrollment: 711
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 45
- YouTube: 17
- Podcasts: 15

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=tropics-04-nct04527991

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04527991", "email": "<work email>"}; the inbox owner confirms by the emailed link.